Who are Eculizumab Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Piasky, PIASKY, Eculizumab (Soliris®), C5 Inhibitor, BOL-303259-X, Spacing of Eculizumab infusions.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/eculizumab-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Eculizumab Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Eculizumab Injection (Eculizumab Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C5 inhibitor. Area: Immunology.

phase 3 Complement C5 inhibitor C5 (Complement protein 5) Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Eculizumab Injection (Eculizumab Injection) — Wuhan Createrna Science and Technology Co., Ltd. Eculizumab is a monoclonal antibody that inhibits the complement protein C5, blocking the formation of the membrane attack complex and reducing complement-mediated cell destruction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Eculizumab Injection TARGET	Eculizumab Injection	Wuhan Createrna Science and Technology Co., Ltd	phase 3	Complement C5 inhibitor	C5 (Complement protein 5)
Piasky	CROVALIMAB	Genentech Inc	marketed	Complement C5 Inhibitor [EPC]		2025-01-01
PIASKY	CROVALIMAB-AKKZ	GENENTECH INC	marketed	Complement C5 Inhibitor [EPC]
Eculizumab (Soliris®)	Eculizumab (Soliris®)	Massachusetts General Hospital	marketed	Complement C5 inhibitor	Complement protein C5
C5 Inhibitor	C5 Inhibitor	Alexion Pharmaceuticals, Inc.	phase 3	Complement C5 inhibitor	C5
BOL-303259-X	BOL-303259-X	Bausch & Lomb Incorporated	phase 3	Complement C5 inhibitor	Complement C5
Spacing of Eculizumab infusions	Spacing of Eculizumab infusions	University Hospital, Tours	phase 3	Complement C5 inhibitor	Complement protein C5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement C5 inhibitor class)

Alexion Pharmaceuticals, Inc. · 1 drug in this class
Bausch & Lomb Incorporated · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
University Hospital, Tours · 1 drug in this class
Wuhan Createrna Science and Technology Co., Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Eculizumab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/eculizumab-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing